A COMPARATIVE STUDY OF DOXYLAMINE SUCCINATE WITH PYRIDOXINE HYDROCHLORIDE AND ONDANSETRON IN TREATING UREMIA-INDUCED NAUSEA AND VOMITING IN CHRONIC RENAL FAILURE PATIENTS

Objective: Advanced-stage chronic kidney disease (CKD) patients often complain of uremic dyspeptic syndrome specifically nausea and vomiting. This is a distressing phenomenon that compromises the patients’ quality of life. There is no guideline available for a complete cure for nausea and vomiting in CKD. The objective of this study was to evaluate and compare the effect of doxylamine succinate with pyridoxine hydrochloride and routinely used ondansetron in improving the symptoms of non-dialyzed conservative CKD patients. Methods: A randomized, open-label, comparative study was done with 70 patients in the doxylamine succinate-pyridoxine group and 65 in the ondansetron group, a total of 135 patients completed the study. The study duration was 7 days. A catboost regression on the response of area under curve matric was carried out to compare the visual analog scale (VAS) score differences. Analysis of covariance and Wilcoxon signed-rank test was used to compare biochemical parameters and quality of life (SF-36) scores of both groups. Results: It was observed that there was a stark difference in the VAS score (nausea scale) for the non-dialysis patients in doxylamine succinate-pyridoxine hydrochloride in comparison to the ondansetron. Among the different measures of quality of life, physical function, physical role, and social function were found to be significantly improved by doxylamine succinate-pyridoxine hydrochloride as compared to ondansetron. Conclusion: Doxylamine succinate-pyridoxine hydrochloride is frequently prescribed for pregnancy-induced nausea and vomiting but is also effective in reducing uremia-induced nausea and vomiting symptoms in conservative CKD patients